Effect of denture-related stomatitis fluconazole treatment on oral Candida albicans susceptibility profile and genotypic variability

• Type: Article in International Scientific Journal
• Date: 2015

Authors

Maria Helena Figueiral (Author) FMDUP; Patrícia Fonseca (Author) FMDUP; Lopes, MM (Author) Other; Pinto, E (Author) FFUP; Pereira Leite, T (Author) Other; Benedita Sampaio-Maia (Author) FMDUP

Journal

Title: Open Dentistry Journal

Vol. 9

Pages: 46-51

ISSN: 1874-2106

Publisher: Bentham Science

Indexing

ISI Web of Knowledge

ISI Web of Science

Scopus - 22 Citations

Pubmed / Medline

Scientific classification

CORDIS: Health sciences

Other information

Authenticus ID: P-00A-A73

DOI: 10.2174/1874210601509010046.

Abstract (EN): Denture-related stomatitis (DRS) is the most common condition affecting removable-denture wearers, and Candida albicans the most frequent pathogenic agent. Systemic antifungal treatment is indicated but recurrences are frequent. The aim of this study was to characterize the oral load, fluconazole susceptibility profile and genotypic variability of oral C. albicans isolates from patients with DRS before (T0), immediately after fluconazole treatment (Tat) and after 6-months follow-up (T6m). Eighteen patients presenting DRS and treated with fluconazole were followed at the Faculty of Dentistry of Oporto University. Seventy C. albicans isolates were obtained and identified using standard cultural and biochemical multi-testing. Fluconazole susceptibility was tested by E-test®. Microsatellite-primed PCR was performed to assess the genotypic variability of C. albicans isolates. The patients’ mean age was 58.0±3.2 years, and 55.6%/44.4% had total/partial dentures. Before treatment, 22.2%, 44.4% and 33.3% of the patients presented DRS type I, II or III, respectively. Fluconazole treatment healed or improved DRS in 77.8% of the patients, accompanied by an 83.5% reduction in oral C. albicans load. However, after 6-months, oral C. albicans load increased significantly and DRS severity was similar to the one observed before treatment. Moreover, the prevalence of patients presenting fluconazole resistant isolates of C. albicans increased significantly throughout the study: T0-5.6%, Tat-10.0% and T6m-42.9%. A change in the genotypic variability of C. albicans isolates was also verified, being mostly associated to fluconazole susceptibility profile change. In conclusion, fluconazole presents a good short-term DRS treatment efficiency, but may be associated to a long-term emergence of C. albicans fluconazole resistance. © Figueiral et al.; Licensee Bentham Open.

Language: English

Type (Professor's evaluation): Scientific